- Home
- PAMT vs ABEO Comparison
PAMT vs ABEO Comparison
Compare PAMT & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAMT
- ABEO
- Stock Information
- Founded
- PAMT 1980
- ABEO 1974
- Country
- PAMT United States
- ABEO United States
- Employees
- PAMT N/A
- ABEO N/A
- Industry
- PAMT Trucking Freight/Courier Services
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- PAMT Industrials
- ABEO Health Care
- Exchange
- PAMT Nasdaq
- ABEO Nasdaq
- Market Cap
- PAMT 301.4M
- ABEO 256.9M
- IPO Year
- PAMT 1985
- ABEO 1980
- Fundamental
- Price
- PAMT $12.31
- ABEO $6.28
- Analyst Decision
- PAMT Hold
- ABEO Strong Buy
- Analyst Count
- PAMT 1
- ABEO 6
- Target Price
- PAMT $12.50
- ABEO $18.00
- AVG Volume (30 Days)
- PAMT 28.4K
- ABEO 1.6M
- Earning Date
- PAMT 07-23-2025
- ABEO 05-15-2025
- Dividend Yield
- PAMT N/A
- ABEO N/A
- EPS Growth
- PAMT N/A
- ABEO N/A
- EPS
- PAMT N/A
- ABEO N/A
- Revenue
- PAMT $687,396,000.00
- ABEO N/A
- Revenue This Year
- PAMT N/A
- ABEO N/A
- Revenue Next Year
- PAMT $9.03
- ABEO $383.07
- P/E Ratio
- PAMT N/A
- ABEO N/A
- Revenue Growth
- PAMT N/A
- ABEO N/A
- 52 Week Low
- PAMT $11.01
- ABEO $3.93
- 52 Week High
- PAMT $23.70
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- PAMT N/A
- ABEO 57.21
- Support Level
- PAMT N/A
- ABEO $5.93
- Resistance Level
- PAMT N/A
- ABEO $7.17
- Average True Range (ATR)
- PAMT 0.00
- ABEO 0.42
- MACD
- PAMT 0.00
- ABEO -0.01
- Stochastic Oscillator
- PAMT 0.00
- ABEO 52.15
About PAMT PAMT CORP Common Stock
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.